Interventional Radiology Imaging

What Is the Next Step for a Persistent 1-3 cm Ground-Glass Lung Nodule?

·
What Is the Next Step for a Persistent 1-3 cm Ground-Glass Lung Nodule?

It’s late in your clinic day, and you’re reviewing a follow-up chest CT for a 64-year-old patient. Three months ago, an incidental 1.5 cm ground-glass nodule (GGO) was found in the right upper lobe. Today’s scan shows it’s still there, unchanged. While many GGOs are benign and transient, persistence raises suspicion for an early-stage primary lung adenocarcinoma. The patient is asymptomatic and anxious for a definitive plan. This clinical workflow article addresses the specific question of the next best step in this scenario, where the need for a tissue diagnosis has become paramount. According to the American College of Radiology (ACR) Appropriateness Criteria, the next step is clear: a Percutaneous lung biopsy is rated as Usually appropriate.

Who Fits This Clinical Scenario?

This guidance is for an adult patient with a solitary pulmonary nodule that meets specific criteria. The nodule must be between 1 and 3 cm in diameter and have a pure ground-glass or mostly ground-glass appearance on computed tomography (CT). Critically, this workflow applies only after the nodule has been shown to be persistent on a short-interval follow-up CT scan, typically performed at 3-6 months. The clinical and radiologic findings should be suspicious for a primary lung adenocarcinoma, such as a lack of infectious symptoms or the absence of features suggesting a benign etiology.

This article does not apply to several similar-sounding but distinct clinical situations:

  • Solid Pulmonary Nodules: A nodule that is entirely soft-tissue density has a different differential diagnosis and risk profile. An enlarging solid nodule, for instance, often requires a more aggressive workup.
  • Stable, Long-Term Nodules: A nodule, even a solid one, that has been stable in size and appearance for two or more years is generally considered benign and may not require intervention.
  • Multiple Nodules: The presence of multiple nodules changes the differential to include metastatic disease or infectious/inflammatory processes, requiring a different diagnostic algorithm.

The focus here is squarely on the solitary, persistent GGO where the primary concern has shifted from watchful waiting to active diagnosis.

What Diagnoses Are You Working Up in This Scenario?

When a ground-glass nodule persists, the differential diagnosis narrows, and the suspicion for malignancy increases significantly. The imaging workup and subsequent biopsy are aimed at distinguishing between a few key possibilities along the adenocarcinoma spectrum and less common benign causes.

Primary Lung Adenocarcinoma: This is the principal concern. Persistent GGOs are the classic radiographic appearance for the pre-invasive and early invasive stages of lung adenocarcinoma. This includes adenocarcinoma in situ (AIS), which is a pre-invasive lesion confined to the alveolar lining, and minimally invasive adenocarcinoma (MIA), which shows a small focus of invasion. Differentiating these from invasive adenocarcinoma is critical for prognosis and treatment planning, and a tissue sample is the definitive way to do so.

Atypical Adenomatous Hyperplasia (AAH): This is considered a pre-malignant lesion and a precursor to adenocarcinoma in situ. On imaging, AAH is often indistinguishable from AIS. While not frank cancer, identifying AAH on biopsy signals a high-risk state that requires close surveillance or, in some cases, excision.

Focal Inflammation or Organizing Pneumonia: Although less likely given the nodule’s persistence without change over several months, a chronic, low-grade inflammatory process or a small focus of organizing pneumonia can sometimes mimic a GGO. Most infectious or inflammatory nodules would be expected to resolve or change significantly on short-interval follow-up, but persistence can occasionally occur.

Focal Interstitial Fibrosis: A small area of scarring in the lung can sometimes present as a ground-glass opacity. However, this is typically a diagnosis of exclusion after malignancy has been ruled out, and it would be expected to remain stable over a much longer period.

Why Is Percutaneous Lung Biopsy the Recommended Study for This Presentation?

For a persistent and suspicious 1-3 cm ground-glass nodule, obtaining a tissue diagnosis is the logical and necessary next step to guide management. The ACR designates Percutaneous lung biopsy as Usually appropriate because it directly addresses this need with high diagnostic yield and acceptable risk.

A CT-guided percutaneous biopsy allows an interventional radiologist to precisely target the nodule, even if it is hazy and ill-defined, and obtain core samples for histopathologic analysis. This provides the crucial information to confirm or exclude malignancy and, if present, to subtype the cancer, which is essential for modern oncologic therapy. The procedure is minimally invasive compared to surgical options and is highly effective for peripheral nodules, which is a common location for GGOs.

Other options are rated lower for specific reasons in this context:

  • Endobronchial ultrasound and biopsy (EBUS) is rated May be appropriate. While a powerful tool, its utility is highest for central lesions or for sampling mediastinal and hilar lymph nodes. For a peripheral GGO, the diagnostic yield of EBUS is generally lower than that of a direct percutaneous approach.
  • Surgical management (i.e., proceeding directly to resection without a biopsy) is rated Usually not appropriate. Subjecting a patient to the risks of thoracic surgery without a confirmed cancer diagnosis is overly aggressive. The goal is to confirm malignancy first, then proceed with the appropriate surgical or non-surgical treatment.
  • Follow-up imaging only is rated May be appropriate, but this choice implies stepping back from a diagnosis. Given that the scenario specifies the nodule has already persisted on one follow-up and is suspicious, further waiting often just delays a necessary diagnosis. A tissue sample is needed to break the cycle of surveillance.

The primary risk of percutaneous biopsy is pneumothorax (collapsed lung), though the majority are small and resolve without intervention. Bleeding is another, less common risk. These procedural risks are generally considered acceptable when weighed against the need for a definitive diagnosis of potential lung cancer.

What’s Next After Percutaneous Lung Biopsy? Downstream Workflow

The pathology results from the biopsy dictate the subsequent clinical pathway. The workflow diverges significantly based on whether the findings are malignant, benign, or high-risk.

If the result is positive for adenocarcinoma (AIS, MIA, or invasive): The patient requires staging to determine the extent of the disease. This typically involves a PET/CT scan to look for nodal or distant metastases and a brain MRI, as lung cancer commonly spreads to the brain. Following staging, the patient should be referred to a multidisciplinary team, including a thoracic surgeon, medical oncologist, and radiation oncologist, to determine the optimal treatment plan, which is most often surgical resection for early-stage disease.

If the result is negative for malignancy (e.g., shows inflammation or fibrosis): This result must be interpreted with caution. A negative biopsy can sometimes be due to sampling error, especially with diffuse GGOs. The next step is a discussion between the radiologist, pulmonologist, and referring physician. If the clinical and imaging suspicion for cancer remains high despite the negative biopsy, options include a repeat biopsy, proceeding to surgical excision for diagnosis, or continuing with close CT surveillance to ensure stability.

If the result is indeterminate or high-risk (e.g., Atypical Adenomatous Hyperplasia): This finding confirms the nodule is on the pre-malignant spectrum. Management requires a multidisciplinary tumor board discussion. Depending on the patient’s surgical fitness, the size and characteristics of the nodule, and patient preference, the recommendation may be surgical resection (to be both diagnostic and therapeutic) or continued, very close CT surveillance.

Pitfalls to Avoid (and When to Get Help)

Navigating the workup of a persistent GGO requires careful attention to detail to avoid common missteps. First, be certain the nodule is truly pure ground-glass; the development of a new solid component is a significant sign of progression to invasive cancer and increases the urgency of the workup. Second, do not underestimate the technical challenges of biopsying a faint GGO. Ensure the procedure is performed at a center with experienced interventional radiologists. Finally, a negative or indeterminate biopsy result is not an endpoint; it is a decision point. Never dismiss a suspicious nodule based on a single non-malignant biopsy without careful clinical and radiologic correlation. If the biopsy result does not align with the imaging findings, escalate the case to a multidisciplinary tumor board for consensus recommendations.

Related ACR Topics and Tools

This article covers one specific clinical variant in depth. For a broader view of managing all types of pulmonary nodules and for tools to assist in ordering the correct imaging studies, the following resources are available:

Frequently Asked Questions

What officially defines a ground-glass nodule as ‘persistent’?

Persistence is generally established when a ground-glass nodule remains stable in size and appearance or grows on a short-term follow-up CT scan, typically performed 3 to 6 months after its initial discovery. Transient nodules, often caused by infection or inflammation, would be expected to resolve or significantly decrease in size over this period.

Why not just proceed to surgical resection instead of a biopsy first?

According to the ACR, proceeding directly to surgery is ‘Usually not appropriate’ because it exposes the patient to the significant risks of a surgical procedure without a confirmed diagnosis of cancer. A percutaneous biopsy is a much less invasive way to establish a tissue diagnosis. If the nodule proves to be benign, a major surgery can be avoided.

What are the main risks of a percutaneous lung biopsy for a GGO?

The most common risk is pneumothorax (air leak around the lung), which occurs in a significant minority of patients but usually resolves on its own without requiring a chest tube. The second most common risk is minor bleeding along the biopsy tract (pulmonary hemorrhage), which is typically self-limiting. More serious complications are rare when the procedure is performed by an experienced interventional radiologist.

If the biopsy is negative, does that definitively mean the nodule is not cancer?

Not necessarily. A negative biopsy can sometimes represent a ‘sampling error,’ meaning the needle missed the malignant cells within the nodule. If the radiologic suspicion for cancer remains high despite a negative biopsy, the case should be discussed by a multidisciplinary team. Further steps might include closer CT surveillance, a repeat biopsy, or surgical excision for a definitive diagnosis.

Is endobronchial ultrasound (EBUS) ever a better choice for a ground-glass nodule?

EBUS is rated ‘May be appropriate’ and can be a better choice in specific situations. It is most effective for nodules located in the central part of the lungs, close to the major airways. For the more common peripheral GGOs, a CT-guided percutaneous biopsy generally offers a more direct route and a higher diagnostic yield.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026